Recursion Pharmaceuticals (RXRX)
Market Price (3/28/2026): $2.95 | Market Cap: $1.5 BilSector: Health Care | Industry: Biotechnology
Recursion Pharmaceuticals (RXRX)
Market Price (3/28/2026): $2.95Market Cap: $1.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -43% | Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -120% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -648 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -873% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -59% | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.67 | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 150% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, and Biopharmaceutical R&D. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -501%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -512% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 33% | ||
| Key risksRXRX key risks include [1] the lack of late-stage clinical validation for its core AI-driven discovery platform and [2] a history of discontinued drug candidates that creates uncertainty about the platform’s ability to perform as expected. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -43% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -59% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, and Biopharmaceutical R&D. |
| Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -120% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.67 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -648 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -873% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 150% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -501%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -512% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 33% |
| Key risksRXRX key risks include [1] the lack of late-stage clinical validation for its core AI-driven discovery platform and [2] a history of discontinued drug candidates that creates uncertainty about the platform’s ability to perform as expected. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Institutional Investor Exits. High-profile institutional investors, including NVIDIA and Mubadala Investment Co PJSC, notably exited their positions or significantly reduced their stakes in Q4 2025. NVIDIA Corporation removed 7,706,363 shares, an estimated value of $31,519,024, and Mubadala Investment Co PJSC removed 12,985,927 shares, an estimated value of $53,112,441, indicating a substantial loss of institutional confidence in the company.
2. Substantial Insider Selling Activity. Over the 90 days leading up to March 13, 2026, company insiders engaged in significant selling activity exceeding $8 million in total value, with no recorded buy transactions. This includes notable sales by Director Blake Borgeson totaling over $1.8 million, and other officers, signaling a lack of confidence from company executives.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.5% change in RXRX stock from 11/30/2025 to 3/27/2026 was primarily driven by a -56.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.63 | 2.94 | -36.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43 | 74 | 71.0% |
| P/S Multiple | 47.7 | 20.7 | -56.7% |
| Shares Outstanding (Mil) | 447 | 522 | -14.3% |
| Cumulative Contribution | -36.5% |
Market Drivers
11/30/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| RXRX | -36.5% | |
| Market (SPY) | -5.3% | 35.6% |
| Sector (XLV) | -8.7% | 27.6% |
Fundamental Drivers
The -37.4% change in RXRX stock from 8/31/2025 to 3/27/2026 was primarily driven by a -32.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.70 | 2.94 | -37.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 65 | 74 | 15.1% |
| P/S Multiple | 30.4 | 20.7 | -32.0% |
| Shares Outstanding (Mil) | 417 | 522 | -20.0% |
| Cumulative Contribution | -37.4% |
Market Drivers
8/31/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| RXRX | -37.4% | |
| Market (SPY) | 0.6% | 45.5% |
| Sector (XLV) | 5.2% | 30.7% |
Fundamental Drivers
The -60.9% change in RXRX stock from 2/28/2025 to 3/27/2026 was primarily driven by a -52.2% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.51 | 2.94 | -60.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58 | 74 | 27.0% |
| P/S Multiple | 43.2 | 20.7 | -52.2% |
| Shares Outstanding (Mil) | 336 | 522 | -35.5% |
| Cumulative Contribution | -60.9% |
Market Drivers
2/28/2025 to 3/27/2026| Return | Correlation | |
|---|---|---|
| RXRX | -60.9% | |
| Market (SPY) | 9.8% | 53.1% |
| Sector (XLV) | -2.1% | 40.4% |
Fundamental Drivers
The -63.9% change in RXRX stock from 2/28/2023 to 3/27/2026 was primarily driven by a -64.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3272026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.15 | 2.94 | -63.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 40 | 74 | 87.1% |
| P/S Multiple | 38.2 | 20.7 | -45.9% |
| Shares Outstanding (Mil) | 186 | 522 | -64.4% |
| Cumulative Contribution | -63.9% |
Market Drivers
2/28/2023 to 3/27/2026| Return | Correlation | |
|---|---|---|
| RXRX | -63.9% | |
| Market (SPY) | 69.4% | 39.8% |
| Sector (XLV) | 18.4% | 25.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RXRX Return | -45% | -55% | 28% | -31% | -39% | -23% | -90% |
| Peers Return | -44% | -39% | 0% | -44% | 18% | -16% | -81% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| RXRX Win Rate | 22% | 33% | 42% | 33% | 58% | 33% | |
| Peers Win Rate | 38% | 38% | 50% | 33% | 50% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| RXRX Max Drawdown | -48% | -71% | -41% | -42% | -43% | -23% | |
| Peers Max Drawdown | -51% | -56% | -42% | -50% | -29% | -26% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SDGR, RLAY, ABCL, CERT, LTRN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | RXRX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.0% | -25.4% |
| % Gain to Breakeven | 806.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to SDGR, RLAY, ABCL, CERT, LTRN
In The Past
Recursion Pharmaceuticals's stock fell -89.0% during the 2022 Inflation Shock from a high on 7/13/2021. A -89.0% loss requires a 806.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Recursion Pharmaceuticals (RXRX)
AI Analysis | Feedback
Here are 1-3 brief analogies for Recursion Pharmaceuticals (RXRX):
- Amazon for drug discovery
- Google for decoding biology
AI Analysis | Feedback
```html- REC-994: A drug candidate in Phase IIa clinical trial for treating cerebral cavernous malformation.
- REC-2282: A drug candidate for the treatment of neurofibromatosis type 2.
- REC-4881: A drug candidate to treat familial adenomatous polyposis.
- REC-3599: A drug candidate in Phase I clinical trial for treating GM2 gangliosidosis.
- REC-3964: A preclinical stage drug candidate to treat Clostridium difficile colitis.
- REC-64917: A preclinical stage drug candidate for the treatment of neural or systemic inflammation.
- REC-65029: A preclinical stage drug candidate to treat HRD-negative ovarian cancer.
- REC-648918: A preclinical stage drug candidate designed to enhance anti-tumor immune response.
- REC-2029: A preclinical stage drug candidate for the treatment of wnt-mutant hepatocellular carcinoma.
- REC-14221: A preclinical stage drug candidate to treat solid and hematological malignancies.
- REC-64151: A preclinical stage drug candidate for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
AI Analysis | Feedback
Recursion Pharmaceuticals (RXRX) operates as a clinical-stage biotechnology company focused on drug discovery and development. Given the nature of its business, which involves developing drug candidates and technological platforms for drug discovery, the company primarily sells to other companies and institutions through collaborations and agreements rather than directly to individuals.
Based on the provided information, the major customer companies (or strategic partners acting in a customer-like capacity for its technology and drug candidates) include:
- Bayer AG (OTCMKTS: BAYRY)
- Takeda Pharmaceutical Company Limited (NYSE: TAK)
AI Analysis | Feedback
nullAI Analysis | Feedback
Najat Khan, Ph.D. CEO and President
Dr. Najat Khan assumed the role of CEO and President of Recursion Pharmaceuticals on January 1, 2026. She brings deep expertise from the pharmaceutical and healthcare industry, integrating scientific discovery, data, technology, and business strategy. Prior to becoming CEO, Dr. Khan served as Recursion's Chief R&D and Commercial Officer and was instrumental in advancing multiple clinical programs and leading the company's combination with Exscientia. Before joining Recursion in 2024, she was the Chief Data Science Officer and Senior Vice President at Johnson & Johnson Innovative Medicine.
Ben Taylor Chief Financial Officer & President Recursion UK
Ben Taylor was appointed Chief Financial Officer (and President Recursion UK) effective November 20, 2024, following Recursion's acquisition of Exscientia. He previously served for over four years as the CFO of Exscientia. Mr. Taylor has more than two decades of experience in healthcare investment banking and executive roles, including 15 years at Goldman Sachs and Barclays, where he focused on financing, strategic, and cross-border transactions in the biopharmaceutical industry across the U.S., Asia, and Europe. He also served as President and CFO for Tyme Technologies, a NASDAQ-listed oncology-focused biotechnology company, guiding its advancement from Phase 1 to Phase 3. Before Exscientia, he was interim CFO at Aetion, a healthtech company.
Chris Gibson, Ph.D. Co-Founder and Board Chair
Dr. Chris Gibson co-founded Recursion Pharmaceuticals in 2013 and served as its CEO from founding through 2025, building it into a publicly listed TechBio company. He is now the Co-Founder and Board Chair. Dr. Gibson developed the foundational technology for Recursion during his MD/PhD studies in Dr. Dean Li's lab at the University of Utah. He holds undergraduate degrees in bioengineering and management from Rice University. Dr. Gibson is active as an advisor and mentor to emerging biotech founders.
Tina Larson Chief Operating Officer
Tina Larson is the Chief Operating Officer at Recursion Pharmaceuticals, a role she assumed in 2018. In this position, she oversees technical operations, including the company’s automated screening platform, and core business functions. Prior to joining Recursion, Ms. Larson was the Senior Vice President of Technical Operations at Achaogen, where she established their Technical Operations organization. She also spent 20 years at Genentech and Roche, holding leadership positions in Technical Development, Manufacturing, and Engineering, and contributed to every commercial biopharmaceutical product launched from Genentech during her tenure.
David Hallett, Ph.D. Chief Scientific Officer
Dr. David Hallett serves as the Chief Scientific Officer at Recursion. He joined Recursion following approximately five years as the Chief Scientific Officer and Interim CEO of Exscientia. Dr. Hallett is an experienced "drug hunter" with over two decades of experience leading scientific teams and driving strategic collaborations in the pharmaceutical and biotechnology industries. Before Exscientia, from 2005 to 2019, he held various positions at Evotec, including Executive Vice President of Chemistry and EVP of Alliance Management. He also served as a Research Fellow at Merck & Co., Inc.
AI Analysis | Feedback
The key risks to Recursion Pharmaceuticals (RXRX) are as follows:- Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biotechnology company, Recursion Pharmaceuticals' success is heavily dependent on its drug candidates successfully progressing through various phases of clinical trials and ultimately receiving regulatory approval. The company has multiple programs in Phase I and Phase IIa clinical trials, and many more in preclinical stages. A failure in any of these stages due to lack of efficacy, unexpected side effects, or an inability to meet regulatory requirements could significantly delay or terminate the development of a drug, leading to substantial financial losses and a negative impact on the company's prospects.
- Significant Capital Requirements and Funding Risk: Developing and bringing a new drug to market is an extremely capital-intensive process, especially for a company with multiple drug candidates in various stages of development. Recursion Pharmaceuticals, as a clinical-stage entity, is likely to incur substantial research and development expenses without significant product revenue. The company may need to raise additional capital through equity offerings, debt financing, or strategic partnerships, which could dilute existing shareholders or be difficult to secure on favorable terms, posing a risk to its ability to fund ongoing operations and future development.
- Competition and Intellectual Property Risk: The biotechnology and pharmaceutical industries are highly competitive. Recursion Pharmaceuticals' drug candidates could face competition from other companies developing similar treatments for the same diseases, potentially through different mechanisms or more advanced stages of development. Furthermore, the company's ability to protect its proprietary technology and drug candidates through patents and other intellectual property rights is crucial. Any challenges to its intellectual property, inability to obtain new patents, or expiration of existing patents could negatively impact its competitive position and future revenue potential.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable markets for Recursion Pharmaceuticals' main products are as follows:
- REC-994 (Cerebral Cavernous Malformation): The global cerebral cavernous malformation market was valued at USD 415.63 million in 2024 and is projected to reach USD 628.25 million by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period. North America holds the largest share of this market, with the U.S. accounting for a significant portion within North America.
- REC-2282 (Neurofibromatosis Type 2): The Neurofibromatosis Type-2 market in the G-8 region was valued at USD 188.09 million in 2020. The United States accounts for the highest market size for Neurofibromatosis Type-2 compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China. The Neurofibromatosis Type 2 market in the 7MM (United States, EU4, the UK, and Japan) is anticipated to experience steady growth with a robust CAGR from 2024 to 2034.
- REC-4881 (Familial Adenomatous Polyposis): The global familial adenomatous polyposis treatment market size was valued at USD 2.09 billion in 2024 and is expected to reach USD 6.42 billion by 2032, at a CAGR of 15.00%. North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2025, with the U.S. capturing 82% of the revenue share within North America in 2024.
- REC-3599 (GM2 Gangliosidosis): The global GM2 gangliosidosis market is projected to reach an estimated value of USD 270 million in 2024 and is expected to grow to approximately USD 720 million by 2034, exhibiting a strong CAGR of around 10.5% during this period. North America is expected to dominate the GM2 gangliosidosis market.
AI Analysis | Feedback
Recursion Pharmaceuticals (NASDAQ: RXRX) is poised for future revenue growth over the next 2-3 years, driven primarily by its strategic collaborations, the advancement of its wholly-owned clinical pipeline, and the continued expansion and validation of its AI-driven drug discovery platform.
Drivers of Future Revenue Growth:
-
Continued Milestone Payments from Strategic Collaborations: Recursion Pharmaceuticals has established significant partnerships with pharmaceutical giants like Sanofi and Roche/Genentech. Revenue from these collaborations, largely through milestone payments, has been a key driver of the company's financial performance. For instance, Recursion's Q4 2025 revenue was significantly bolstered by milestone payments from both Roche/Genentech and Sanofi. The Sanofi collaboration has already generated $134 million ($100 million upfront and $34 million in milestones), with expectations for further later-stage discovery milestones over the next 18 months. Similarly, the partnership with Roche and Genentech has yielded $213 million in upfront and milestone payments to date, with potential for additional upcoming milestones. Analysts are forecasting a significant acceleration in revenue for Recursion, with collaboration milestones being a primary income source.
-
Advancement of the Wholly-Owned Clinical Pipeline: The progression of Recursion's internal drug candidates through clinical trials is expected to generate significant value and potential future revenue. The company currently has five differentiated clinical programs advancing with defined next-stage milestones. A notable example is REC-4881, a program for Familial Adenomatous Polyposis (FAP), which has demonstrated positive Phase 2 proof of concept with a 43% median reduction in polyp burden in patients. Recursion plans to engage with the FDA in the first half of 2026 to discuss a registration pathway for REC-4881, and additional data is anticipated in early 2027. Other pipeline assets, such as RBM39, CDK7, ENPP1, MALT1, and LSD1, also have upcoming catalysts including early safety and pharmacokinetic data or go/no-go decisions expected within the next 18-24 months. The successful advancement of these programs could lead to further milestone payments, licensing deals, or, in the longer term, product sales.
-
Expansion and Validation of the AI-Driven Drug Discovery Platform: Recursion's proprietary AI-driven drug discovery platform, the "Recursion OS," is a core asset that continually drives new opportunities for revenue growth. The company is at an "important inflection point" in translating its platform's insights into tangible evidence for generating effective medicines. The acquisition of Exscientia in November 2024 has further strengthened Recursion's capabilities by integrating AI-enabled chemistry and molecular design into its existing phenomics platform. This enhanced platform is expected to attract new partnerships and expand existing collaborations, leading to additional upfront payments and milestone revenues. Management has emphasized a strategic focus on scaling generative drug design and applying AI across the full life cycle of R&D, positioning the company as a leader in AI-native drug discovery.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- Recursion Pharmaceuticals significantly increased its outstanding shares from 0.169 billion in December 2021 to 0.447 billion in December 2025, indicating substantial share issuance.
- The company bolstered its cash position through multiple equity raises and an At-The-Market (ATM) equity program, including an offering in June 2024.
- Recursion secured a new $500 million ATM offering agreement with Citigroup in February 2025.
Inbound Investments
- Recursion has received over $500 million in cumulative upfront and progress-based milestone payments from strategic partners as of February 2026.
- This includes $213 million in cash inflows from its collaboration with Roche and Genentech, and $134 million from its partnership with Sanofi.
- A transformational collaboration with Roche and Genentech was announced in December 2021 to advance up to 40 novel potential medicines in neuroscience and gastrointestinal oncology, and the collaboration with Bayer was expanded in 2021 to include more than a dozen fibrosis programs.
Outbound Investments
- In November 2024, Recursion Pharmaceuticals completed the acquisition of Exscientia plc for $630.1 million, a move aimed at strengthening its AI-enabled drug discovery capabilities. This was identified as the largest merger or acquisition in the TechBio space to date.
Capital Expenditures
- Capital expenditures were reported as $3.91 million in 2025 and $6.5 million in fiscal year 2024.
- Investments have primarily focused on building out the Recursion Operating System (OS), including scaling transcriptomic technologies, enhancing hiPSC-derived cell production, and integrating in-house chemistry capabilities.
- In late 2023, the company announced an expansion of its BioHive-1 supercomputer with NVIDIA, with the goal of making it the fastest supercomputer wholly owned and operated by any biopharma company.
Latest Trefis Analyses
Trade Ideas
Select ideas related to RXRX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.51 |
| Mkt Cap | 0.9 |
| Rev LTM | 75 |
| Op Inc LTM | -185 |
| FCF LTM | -95 |
| FCF 3Y Avg | -131 |
| CFO LTM | -74 |
| CFO 3Y Avg | -94 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 27.0% |
| Rev Chg 3Y Avg | 14.7% |
| Rev Chg Q | 343.5% |
| QoQ Delta Rev Chg LTM | 71.0% |
| Op Mgn LTM | -270.5% |
| Op Mgn 3Y Avg | -633.8% |
| QoQ Delta Op Mgn LTM | 429.2% |
| CFO/Rev LTM | -174.8% |
| CFO/Rev 3Y Avg | -222.2% |
| FCF/Rev LTM | -231.7% |
| FCF/Rev 3Y Avg | -399.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 13.0 |
| P/EBIT | -3.6 |
| P/E | -6.4 |
| P/CFO | -2.4 |
| Total Yield | -15.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -15.7% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.4% |
| 3M Rtn | -33.1% |
| 6M Rtn | -40.2% |
| 12M Rtn | -44.2% |
| 3Y Rtn | -55.5% |
| 1M Excs Rtn | -6.5% |
| 3M Excs Rtn | -26.2% |
| 6M Excs Rtn | -35.6% |
| 12M Excs Rtn | -56.3% |
| 3Y Excs Rtn | -119.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single segment | 59 | 45 | |||
| Grant revenue | 0 | 0 | 1 | ||
| Operating revenue | 40 | 10 | 3 | ||
| Total | 59 | 45 | 40 | 10 | 4 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single segment | -479 | -350 | |||
| Total | -479 | -350 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single segment | -464 | -328 | |||
| Total | -464 | -328 |
Price Behavior
| Market Price | $2.94 | |
| Market Cap ($ Bil) | 1.3 | |
| First Trading Date | 04/16/2021 | |
| Distance from 52W High | -56.7% | |
| 50 Days | 200 Days | |
| DMA Price | $3.76 | $4.75 |
| DMA Trend | down | down |
| Distance from DMA | -21.9% | -38.1% |
| 3M | 1YR | |
| Volatility | 61.1% | 84.3% |
| Downside Capture | 1.80 | 2.45 |
| Upside Capture | 171.72 | 217.66 |
| Correlation (SPY) | 51.0% | 50.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.69 | 3.25 | 2.38 | 3.20 | 2.36 | 2.60 |
| Up Beta | 7.58 | 6.76 | 5.42 | 4.02 | 2.03 | 1.99 |
| Down Beta | 2.08 | 2.30 | 1.04 | 2.41 | 1.95 | 2.48 |
| Up Capture | 194% | 234% | 144% | 367% | 535% | 6288% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 5 | 15 | 21 | 48 | 103 | 341 |
| Down Capture | 379% | 282% | 257% | 266% | 169% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 14 | 24 | 36 | 71 | 140 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXRX | |
|---|---|---|---|---|
| RXRX | -49.8% | 84.2% | -0.46 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 40.2% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 50.6% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 10.2% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 18.0% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 37.4% |
| Bitcoin (BTCUSD) | -21.0% | 44.0% | -0.41 | 38.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXRX | |
|---|---|---|---|---|
| RXRX | -37.0% | 94.6% | -0.08 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 26.4% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 41.0% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 7.4% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 7.4% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 30.9% |
| Bitcoin (BTCUSD) | 4.7% | 56.6% | 0.30 | 20.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RXRX | |
|---|---|---|---|---|
| RXRX | -20.6% | 94.6% | -0.08 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 26.4% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 41.0% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 7.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 7.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 30.9% |
| Bitcoin (BTCUSD) | 66.9% | 66.8% | 1.06 | 20.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/25/2026 | 6.8% | 0.3% | -10.2% |
| 11/5/2025 | -0.8% | -5.8% | -5.8% |
| 8/5/2025 | -4.7% | -8.8% | -20.2% |
| 2/28/2025 | -2.1% | -18.6% | -24.3% |
| 11/6/2024 | -0.6% | 5.0% | 14.9% |
| 8/8/2024 | 4.2% | -1.4% | -7.1% |
| 5/9/2024 | -0.5% | 10.1% | -0.2% |
| 2/27/2024 | -16.6% | -23.3% | -34.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 11 | 6 |
| # Negative | 11 | 7 | 12 |
| Median Positive | 6.7% | 5.0% | 34.2% |
| Median Negative | -2.1% | -15.5% | -11.2% |
| Max Positive | 12.0% | 39.8% | 67.2% |
| Max Negative | -17.7% | -23.3% | -34.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/25/2026 | Prior: Q3 2025 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Operating Cash Expense | 390.00 Mil | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gibson, Christopher | Direct | Sell | 1072026 | 4.25 | 40,000 | 170,000 | 3,968,816 | Form | |
| 2 | Taylor, Ben R | Chief Financial Officer | Direct | Sell | 12302025 | 4.18 | 21,383 | 89,381 | 3,183,279 | Form |
| 3 | Khan, Najat | Chief R&D Commercial Officer | Direct | Sell | 12292025 | 4.41 | 124,403 | 548,592 | 2,694,983 | Form |
| 4 | Gibson, Christopher | Chief Executive Officer | Direct | Sell | 12192025 | 4.50 | 40,000 | 180,000 | 4,112,276 | Form |
| 5 | Gibson, Christopher | Chief Executive Officer | Direct | Sell | 12052025 | 4.63 | 40,000 | 185,200 | 4,323,675 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.